Medical & Surgical Urology
Open Access

Neurogenic Bladder: Navigating Current Treatments and Charting Future Horizons

Osman Crisis^{* *}Correspondence: Osman Crisis, Department of Urology, Worcestershire Royal Hospital, Worcestershire, UK, Email:

Author info »

Description

Neurogenic bladder is a dysfunction of the urinary bladder due to a disease or injury of the Central Nervous System (CNS) or peripheral nerves involved in the control of urination. This condition can result in either an Over-Active Bladder (OAB) or an Under-Active Bladder (UAB), leading to a range of symptoms including urinary incontinence, frequency, urgency, and retention. Managing neurogenic bladder is complex and requires a multifaceted approach [1-3]. Current treatment strategies and future directions in the management of neurogenic bladder.

Current treatment strategies

Improving bladder control and quality of life for patients without the need for more aggressive treatments:

Behavioral therapies: Behavioral therapies are often the first line of treatment for neurogenic bladder. These include bladder training, pelvic floor muscle exercises, and scheduled voiding. These techniques aim to improve bladder control and reduce symptoms without the need for medication or invasive procedures [4-6].

Pharmacological treatments

Current pharmacological treatments for neurogenic bladder aim to manage symptoms and improve bladder function. Here are the main categories and examples:

Anticholinergic agents: These medications, such as oxybutynin and tolterodine, are commonly used to manage overactive bladder symptoms by inhibiting the parasympathetic nervous system, thereby reducing bladder contractions.

Beta-3 adrenergic agonists: Drugs like mirabegron work by relaxing the bladder muscle, increasing storage capacity and reducing episodes of incontinence.

Botulinum toxin (botox) injections: For patients who do not respond to oral medications, Botox injections into the bladder muscle can be an effective treatment. Botox works by temporarily paralyzing the muscles, reducing over activity [7].

Catheterization

Catheterization is a key treatment strategy for managing neurogenic bladder. There are several types of catheterization methods used based on the patient's specific needs and the underlying cause of neurogenic bladder:

Intermittent catheterization: This technique involves periodically inserting a catheter into the bladder to drain urine.

It is often used for patients with underactive bladder or urinary retention.

Indwelling catheterization: In cases where intermittent catheterization is not feasible, an indwelling catheter may be used. This can be either a urethral catheter or a suprapubic catheter, which is inserted through the abdominal wall.

Surgical interventions

These interventions aim to improve bladder function, reduce the risk of Urinary Tract Infections (UTIs), and enhance the quality of life. Here are some common surgical interventions for neurogenic bladder:

Augmentation cystoplasty: This surgery increases the capacity of the bladder by using a segment of the intestine to enlarge the bladder. It is typically reserved for severe cases where other treatments have failed.

Urinary diversion: In extreme cases, the urinary stream is redirected surgically, bypassing the bladder entirely. This might involve creating a stoma on the abdomen, through which urine is collected in an external bag [8-10].

Future directions

As our understanding of neurogenic bladder advances, several promising directions are emerging that could revolutionize treatment.

Regenerative medicine: Regenerative medicine, particularly the use of stem cells, holds significant potential for the treatment of neurogenic bladder. Research is ongoing into how stem cells can be used to repair or regenerate damaged nerves and bladder tissue, potentially restoring normal function.

Gene therapy: Gene therapy involves modifying or introducing genes to correct or treat disease. In the context of neurogenic bladder, gene therapy could target specific genetic abnormalities that contribute to bladder dysfunction. Early studies in animal models have shown promise, but more research is needed before this can become a viable treatment option.

Advanced neuromodulation techniques: Recent developments in neuromodulation are aiming for more precise and minimally invasive nerve stimulation methods. Innovations include closed-loop systems, which adjust stimulation in real-time based on feedback from the bladder.

Improved drug delivery systems: Nanotechnology and other advanced drug delivery systems could enhance the efficacy of pharmacological treatments by delivering drugs directly to the bladder in a controlled manner, reducing side effects and improving outcomes.

Biomaterials and tissue engineering: The development of biomaterials that can mimic the natural properties of bladder tissue is another exciting area of research. These materials could be used in reconstructive surgeries or as scaffolds for tissue engineering, promoting the growth of new, functional bladder tissue.

Personalized medicine: With advancements in genomics and proteomics, personalized medicine tailored to the individual’s genetic makeup and specific disease characteristics is becoming a reality. This approach could lead to more effective and targeted treatments for neurogenic bladder.

Artificial Intelligence (AI) and machine learning: AI and machine learning algorithms can analyses vast amounts of data to identify patterns and predict treatment outcomes. These technologies could assist clinicians in making more informed decisions about the most appropriate treatment strategies for individual patients.

Conclusion

Neurogenic bladder is a challenging condition that requires a comprehensive and individualized approach to treatment. While current strategies include a combination of behavioral therapies, medications, catheterization, and surgical interventions, future directions hold promise for more effective and less invasive treatments. Advances in regenerative medicine, gene therapy, neuromodulation, and personalized medicine, among others, are poised to revolutionize the management of neurogenic bladder, improving outcomes and quality of life for affected individuals. Continued research and clinical trials will be essential to bring these innovations from the laboratory to the clinic, ultimately offering hope for better management of this complex condition.

References

1. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol. 2003;170(2):512-515.

   [Crossref] [Google Scholar] [PubMed].

2. Anderson CA, Omar MI, Campbell SE, Hunter KF, Cody JD, Glazener CM, et al. Conservative management for post-prostatectomy urinary incontinence. Cochrane Database Syst Rev. 2015;1(1):CD001843.

   [Crossref] [Google Scholar] [PubMed].

3. Hubner WA, Schlarp OM. Treatment of incontinence after prostatectomy using a new minimally invasive device: Adjustable continence therapy. BJU Int. 2005;96(4):587-594.

   [Crossref] [Google Scholar] [PubMed].

4. Kielb SJ, Clemens JQ. Comprehensive urodynamic evaluation of 146 men with incontinence after radical prostatectomy. Urology. 2005;66(2):392-396.

   [Crossref] [Google Scholar] [PubMed].

5. Cho ST, Kim KH. Pelvic floor muscle exercise and training for coping with urinary incontinence. J Exerc Rehabil. 2021;17(6):379-387.

   [Crossref] [Google Scholar] [PubMed].

6. Robinson AJ, Snyder-Mackler L. Clinical electrophysiology: Electrotherapy and electrophysiologic testing. 3rd ed. Wolters Kluwer Health/Lippincott Williams and Wilkins. 2008.

   [Google Scholar].

7. Frontera WR, Meredith CN, O’Reilly KP, Knuttgen HG, Evans WJ. Strength conditioning in older men: Skeletal muscle hypertrophy and improved function. J Appl Physiol. 1988;64(3):1038-1044.

   [Crossref] [Google Scholar] [PubMed].

8. Lexell J. Strength training and muscle hypertrophy in older men and women. Top Geriatr Rehabil. 2000;15(3):41-46.

   [Crossref] [Google Scholar].

9. Fornari A, Gressler M, Neis A, Cunha I, Oliveira L, Carboni C, et al. The impact of urinary incontinence on male erectile dysfunction. J Sex Med. 2017;14:e264.

   [Crossref] [Google Scholar].

10. Rohan VS, Hanji AM, Patel JJ, Tankshali RA. Female urethral hemangioma. Saudi J Kidney Dis Transpl 2008;19(4):647-648.

    [Google Scholar] [PubMed].